GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!